Bright Minds Biosciences Inc.

$DRUG is trading near its all-time lows as the company will most likely need to raise more cash to continue operations. In December 2023, the company raised $900,000 to further the progress of Bright Minds’ Phase 2 Clinical Trial for BMB-101, which is furthest along in their pipeline at the moment.

Share This Article

 

About the Author

Bright Minds Biosciences Inc.

Joey Ramson